SCHEMBL3018482

SCHEMBL3018482

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(F)c4)CC3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
KCNQ1 P51787 1/20 0.42
MAPT P10636 5/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GPR6 P46095 3/20 0.41
TP53 P04637 2/20 0.39
LMNA P02545 2/20 0.39
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 1/20 0.38
CCR5 P51681 2/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014493 0.93 MAPT (0.42) SMN1; SMN2KCNQ1MAPTUSP2RECQL
SCHEMBL3014427 0.92 MAPT (0.45) SMN1; SMN2KCNQ1MAPTUSP2RECQL
SCHEMBL3014963 0.91 GPR6 (0.40) SMN1; SMN2KCNQ1MAPTUSP2RECQL
SCHEMBL3014910 0.90 GPR6 (0.42) MAPTUSP2RECQLHSD17B10GPR6
SCHEMBL3011113 0.90 GPR6 (0.42) SMN1; SMN2MAPTUSP2RECQLHSD17B10
SCHEMBL3016542 0.90 TP53 (0.41) SMN1; SMN2MAPTUSP2RECQLHSD17B10
SCHEMBL3014895 0.90 MAPT (0.39) SMN1; SMN2MAPTUSP2RECQLHSD17B10
SCHEMBL3010954 0.90 KCNQ1 (0.42) SMN1; SMN2KCNQ1MAPTUSP2RECQL
SCHEMBL3016039 0.89 MAPT (0.46) SMN1; SMN2KCNQ1MAPTUSP2RECQL
SCHEMBL3009945 0.89 GPR6 (0.42) SMN1; SMN2GPR6RAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885KCNQ1 2702/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.